Trump's controversial administration nominees signal global ramifications for drug regulation, health funding and pharmaceutical investment.
This latest update comes after Advanz secured a suspension of the European Commission’s original revocation in September 2024 ...
The relationship between climate change and infectious disease is raising questions around therapeutic innovation, logistical ...
There are currently no FDA- or EMA-approved treatment options available for any form of frontotemporal dementia.
The US Food and Drug Administration has declined to approve Applied Therapeutics’ govorestat for classic galactosemia.
The EC has granted approval for presentation of GSK's Menveo vaccine (MenACWY) for invasive meningococcal disease (IMD).